Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRN NASDAQ:INCY NASDAQ:IONS NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$54.09-3.3%$58.02$52.93▼$85.00$10.39B0.351.63 million shs1.93 million shsINCYIncyte$83.10-3.6%$78.54$53.56▼$87.99$16.23B0.751.59 million shs1.77 million shsIONSIonis Pharmaceuticals$63.16-1.4%$45.80$23.95▼$64.71$10.07B0.283.22 million shs1.47 million shsUTHRUnited Therapeutics$405.02+0.0%$318.53$266.98▼$436.95$18.27B0.62867,639 shs626,423 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%-6.37%-6.00%-3.82%-36.29%INCYIncyte0.00%-4.09%-4.39%+16.68%+30.74%IONSIonis Pharmaceuticals0.00%+3.15%+44.27%+79.23%+49.70%UTHRUnited Therapeutics0.00%+1.12%+29.35%+40.36%+19.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRNBioMarin Pharmaceutical$54.09-3.3%$58.02$52.93▼$85.00$10.39B0.351.63 million shs1.93 million shsINCYIncyte$83.10-3.6%$78.54$53.56▼$87.99$16.23B0.751.59 million shs1.77 million shsIONSIonis Pharmaceuticals$63.16-1.4%$45.80$23.95▼$64.71$10.07B0.283.22 million shs1.47 million shsUTHRUnited Therapeutics$405.02+0.0%$318.53$266.98▼$436.95$18.27B0.62867,639 shs626,423 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRNBioMarin Pharmaceutical0.00%-6.37%-6.00%-3.82%-36.29%INCYIncyte0.00%-4.09%-4.39%+16.68%+30.74%IONSIonis Pharmaceuticals0.00%+3.15%+44.27%+79.23%+49.70%UTHRUnited Therapeutics0.00%+1.12%+29.35%+40.36%+19.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRNBioMarin Pharmaceutical 2.69Moderate Buy$92.0470.16% UpsideINCYIncyte 2.33Hold$82.53-0.68% DownsideIONSIonis Pharmaceuticals 2.81Moderate Buy$67.887.47% UpsideUTHRUnited Therapeutics 2.69Moderate Buy$438.858.35% UpsideCurrent Analyst Ratings BreakdownLatest IONS, UTHR, BMRN, and INCY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/10/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$405.00 ➝ $525.009/8/2025BMRNBioMarin PharmaceuticalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$60.009/5/2025UTHRUnited TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$510.00 ➝ $575.009/5/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$400.00 ➝ $500.009/4/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$415.00 ➝ $560.009/4/2025INCYIncyteBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$90.00 ➝ $104.009/4/2025IONSIonis PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$70.00 ➝ $80.009/3/2025BMRNBioMarin PharmaceuticalRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$85.009/3/2025IONSIonis PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$69.00 ➝ $84.009/3/2025IONSIonis PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$40.00 ➝ $45.009/3/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$58.00 ➝ $78.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRNBioMarin Pharmaceutical$2.85B3.64$3.25 per share16.66$29.69 per share1.82INCYIncyte$4.24B3.83$0.55 per share150.11$17.90 per share4.64IONSIonis Pharmaceuticals$944.05M10.66N/AN/A$3.73 per share16.93UTHRUnited Therapeutics$2.88B6.35$28.38 per share14.27$144.34 per share2.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRNBioMarin Pharmaceutical$426.86M$3.3716.0512.410.6921.45%12.59%10.13%11/4/2025 (Estimated)INCYIncyte$32.62M$4.4018.8912.710.6518.99%21.99%14.43%11/4/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$1.84N/AN/AN/A-28.25%-45.29%-8.99%11/5/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6215.8114.736.1740.36%18.73%16.49%10/29/2025 (Estimated)Latest IONS, UTHR, BMRN, and INCY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19$0.70+$0.51$0.70$270.90 million$452.00 million7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMRNBioMarin PharmaceuticalN/AN/AN/AN/AN/AINCYIncyteN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRNBioMarin Pharmaceutical0.105.563.60INCYIncyte0.012.852.78IONSIonis Pharmaceuticals0.992.872.86UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRNBioMarin Pharmaceutical98.71%INCYIncyte96.97%IONSIonis Pharmaceuticals93.86%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipBMRNBioMarin Pharmaceutical0.85%INCYIncyte17.80%IONSIonis Pharmaceuticals2.60%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRNBioMarin Pharmaceutical3,040192.01 million190.38 millionOptionableINCYIncyte2,617195.28 million160.52 millionOptionableIONSIonis Pharmaceuticals1,069159.39 million155.07 millionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionableIONS, UTHR, BMRN, and INCY HeadlinesRecent News About These CompaniesSwedbank AB Decreases Stock Position in United Therapeutics Corporation $UTHR2 hours ago | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Integrated Wealth Concepts LLC4 hours ago | marketbeat.comUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Purchases 25,289 Shares of United Therapeutics Corporation $UTHR4 hours ago | marketbeat.comFY2025 EPS Estimates for UTHR Raised by Cantor FitzgeraldSeptember 14 at 6:34 AM | marketbeat.comInspire Investing LLC Sells 1,237 Shares of United Therapeutics Corporation $UTHRSeptember 14 at 5:56 AM | marketbeat.comUTHR FY2025 EPS Forecast Lifted by Cantor FitzgeraldSeptember 14 at 2:29 AM | americanbankingnews.comInsider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $1,588,920.00 in StockSeptember 13 at 8:34 PM | marketbeat.comFY2026 EPS Estimates for UTHR Increased by Cantor FitzgeraldSeptember 13 at 7:54 AM | marketbeat.comAcadian Asset Management LLC Acquires 169,010 Shares of United Therapeutics Corporation $UTHRSeptember 13 at 5:35 AM | marketbeat.comFred Alger Management LLC Makes New $256,000 Investment in United Therapeutics Corporation $UTHRSeptember 13 at 4:08 AM | marketbeat.comEquities Analysts Offer Predictions for UTHR FY2026 EarningsSeptember 13 at 2:43 AM | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Director Sells $280,203.00 in StockSeptember 12 at 5:36 PM | marketbeat.comInsider Selling: United Therapeutics (NASDAQ:UTHR) Director Sells 4,560 Shares of StockSeptember 12 at 5:36 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) COO Sells $1,961,050.00 in StockSeptember 12 at 5:36 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 8,000 SharesSeptember 12 at 5:36 PM | marketbeat.comUnited Therapeutics (NASDAQ:UTHR) COO Sells $4,520,538.75 in StockSeptember 12 at 5:36 PM | marketbeat.comCantor Fitzgerald Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock PriceSeptember 12 at 9:37 AM | marketbeat.com21,112 Shares in United Therapeutics Corporation $UTHR Acquired by Capital Impact Advisors LLCSeptember 12 at 8:17 AM | marketbeat.comMartine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) StockSeptember 12 at 7:25 AM | insidertrades.comUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society CongressSeptember 12 at 7:00 AM | businesswire.comAshton Thomas Private Wealth LLC Has $1.44 Million Stock Position in United Therapeutics Corporation $UTHRSeptember 12 at 5:12 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMedtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Archer's Flight Milestones & Defense Wins Excite Wall Street By Jeffrey Neal Johnson | August 20, 2025Nextracker Stock Rockets as AI and Solar Tailwinds AlignBy Thomas Hughes | August 21, 2025Toll Brothers: A Great Buy and Hold Stock With Risks in 2025By Thomas Hughes | August 21, 2025Insiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift4By Leo Miller | August 18, 2025IONS, UTHR, BMRN, and INCY Company DescriptionsBioMarin Pharmaceutical NASDAQ:BMRN$54.09 -1.82 (-3.26%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$54.44 +0.35 (+0.66%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Incyte NASDAQ:INCY$83.10 -3.07 (-3.56%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$82.09 -1.01 (-1.22%) As of 06:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.Ionis Pharmaceuticals NASDAQ:IONS$63.16 -0.88 (-1.37%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$63.14 -0.01 (-0.02%) As of 06:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.United Therapeutics NASDAQ:UTHR$405.02 +0.18 (+0.04%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$399.94 -5.08 (-1.25%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
